文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

脓毒症患者应激性溃疡预防的疗效与安全性:基于大型数据库的回顾性队列研究

[Efficacy and safety of stress ulcer prophylaxis in septic patients: a retrospective cohort study based on large database].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论在脓毒症成人患者中,应激性溃疡预防未降低院内死亡率、消化道出血和艰难梭菌感染,反而与继发性肺炎风险增加和ICU住院时间延长相关。

该回顾性队列研究基于eICU-CRD数据库,纳入11 413例脓毒症成人患者,其中9 799例在入ICU 48小时内接受质子泵抑制剂或H2受体拮抗剂等应激性溃疡预防(SUP),1 614例未接受。经倾向性评分匹配后,SUP组与未SUP组的院内死亡率、消化道出血和艰难梭菌感染发生率无显著差异,但SUP组继发性肺炎发生率更高(10.9% vs. 6.8%),ICU住院时间更长(3.9天 vs. 3.1天)。亚组分析显示,SUP≥3天与消化道出血风险增加相关(OR=1.84),且SUP≥3天和<3天均与继发性肺炎风险增加相关。

要点

  • 在脓毒症成人患者中,SUP未降低院内死亡率、消化道出血和艰难梭菌感染发生率。
  • 经PSM后,SUP组继发性肺炎发生率显著高于非SUP组(10.9% vs. 6.8%,P<0.05)。
  • 经PSM后,SUP组ICU住院时间显著长于非SUP组(3.9天 vs. 3.1天,P<0.05)。
  • 多因素Logistic回归显示,SUP≥3天与消化道出血风险增加相关(OR=1.84,95%CI 1.07-3.08,P=0.030)。
  • SUP≥3天和<3天均与继发性肺炎风险增加相关(OR分别为2.95和1.34)。

适用人群与场景

  • 成人脓毒症患者,存在消化道出血风险,入住ICU。
  • SUP组定义为入ICU 48小时内接受质子泵抑制剂或H2受体拮抗剂或联合/序贯使用;非SUP组为未接受任何SUP。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 脓毒症诊断标准:原文未提及。
  • 消化道出血风险定义:原文未提及。
  • SUP使用时长分组:SUP≥3天 vs. SUP<3天。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性队列研究,基于eICU-CRD数据库,单数据库多中心(中心数原文未提及)。
  • 样本量:总纳入11 413例,SUP组9 799例,非SUP组1 614例;PSM后每组1 600例。
  • 人群:成人脓毒症患者,SUP组病情更重(APACHE IV评分中位数72 vs. 65,SOFA评分中位数7 vs. 5)。
  • 干预与对照:SUP(PPI或H2RA或联合/序贯) vs. 无SUP。
  • 主要终点结果:PSM前,SUP组院内死亡率17.2% vs. 10.9%,ICU住院时间4.4天 vs. 3.1天,继发性肺炎11.3% vs. 6.8%,均P<0.05;消化道出血和CDI无显著差异。PSM后,院内死亡率、消化道出血和CDI无显著差异;SUP组ICU住院时间3.9天 vs. 3.1天,继发性肺炎10.9% vs. 6.8%,均P<0.05。
  • 亚组分析:SUP≥3天组 vs. SUP<3天组,院内死亡率16.4% vs. 10.7%,消化道出血6.1% vs. 1.8%,继发性肺炎19.0% vs. 8.6%,ICU住院时间6.6天 vs. 3.5天,均P<0.05。
  • 多因素Logistic回归:SUP≥3天 vs. 非SUP组,消化道出血OR=1.84(95%CI 1.07-3.08,P=0.030);SUP<3天 vs. 非SUP组,消化道出血OR=0.57(95%CI 0.34-0.94,P=0.020);继发性肺炎SUP≥3天OR=2.95(95%CI 2.10-4.13,P<0.001),SUP<3天OR=1.34(95%CI 1.01-1.77,P=0.040)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 证据等级或推荐强度:原文未提及。
  • 局限:回顾性设计,单数据库(eICU-CRD),可能存在残余混杂,SUP组病情更重,PSM后仍不能排除未测量混杂。

对床旁实践的改变

  • 在脓毒症成人患者中,常规使用SUP可能不降低院内死亡率、消化道出血和CDI,且与继发性肺炎风险增加和ICU住院时间延长相关。
  • 对于消化道出血风险较低的脓毒症患者,应避免不必要的SUP,尤其是长期使用(≥3天)。
  • 临床决策需权衡SUP的潜在获益与继发性肺炎风险,个体化评估消化道出血风险。
  • 原文未提及适用与不适用人群的具体标准,需结合临床判断。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the effects and safety of stress ulcer prophylaxis (SUP) versus no prophylaxis in adult septic patients at risk of gastrointestinal bleeding (GIB).

METHODS: A retrospective cohort study was conducted, the data was extracted from Electronic Intensive Care Unit-Collaborative Research Database (eICU-CRD). All patients who received proton pump inhibitor (PPI) or H2 receptor antagonist (H2RA) or combined/sequential use for SUP within the first 48 hours of intensive care unit (ICU) admission were enrolled in the SUP group, those who did not received any SUP were enrolled in the non-SUP group. The differences of in-hospital mortality, length of ICU stay (LOS), the incidence of GIB and secondary infection complications between the two groups were compared. Propensity score matching (PSM) was conducted to balance the distributions of study variables between the two groups. Further subgroup analysis was performed according to whether SUP was used for more than 3 days. Multivariate Logistic regression analysis was conducted to analyze the factors influencing the outcome of GIB and secondary pneumonia.

RESULTS: A total of 11 413 patients were included in the final analysis, with 9 799 patients in SUP group and 1 614 in non-SUP group. A 1:1 PSM created 1 600 patients in each cohort. (1) Baseline characteristics: compared with SUP group, patients in non-SUP group were older [years old: 69.0 (56.0, 80.0) vs. 67.0 (56.0, 78.0)], acute physiology and chronic health evaluation IV (APACHE IV) score and sequential organ failure assessment (SOFA) score were significantly lower [APACHE IV score: 65 (50, 73) vs. 72 (58, 87), SOFA score: 5 (4, 7) vs. 7 (5, 9)], higher rates of underlying diseases such as hypertension and diabetes [hypertension: 15.6% (252/1 614) vs. 12.2% (1 196/9 779), diabetes: 4.5% (72/1 614) vs. 3.3% (325/9 779), both P < 0.05], indicating that patients in the SUP group were more severe. (2) Comparison of clinical outcome: before PSM, SUP group had significantly higher in-hospital mortality [17.2% (1 688/9 799) vs. 10.9% (176/1 614)], longer LOS [days: 4.4 (2.9, 7.7) vs. 3.1 (2.5, 4.3)], and higher incidence of secondary pneumonia than non-SUP group [11.3% (1 112/9 799) vs. 6.8% (110/1 614)], with significant differences (all P < 0.05). There was no significant difference in the incidence of GIB and Clostridium difficile infection (CDI) between the two groups. After PSM, no significant differences were observed between the two groups with regard to in-hospital mortality, incidence of GIB and CDI. However, the SUP group had longer LOS [days: 3.9 (2.8, 6.6) vs. 3.1 (2.5, 4.3)], and higher incidence of secondary pneumonia [10.9% (174/1 600) vs. 6.8% (108/1 600)] compared with non-SUP group, the differences were statistically significant (all P < 0.05). Subgroup analysis showed that compared with SUP < 3 days group, patients in SUP ≥ 3 days group had higher disease severity score [APACHE IV score: 66 (51, 79) vs. 62 (48, 72), SOFA score: 6 (4, 8) vs. 5 (4, 7), both P < 0.05], in addition, patients in SUP ≥ 3 days group had higher in-hospital mortality, incidence of GIB and secondary pneumonia (16.4% vs. 10.7%, 6.1% vs. 1.8%, 19.0% vs. 8.6%, respectively), and longer ICU LOS [days: 6.6 (4.1, 11.8) vs. 3.5 (2.6, 5.3), all P < 0.05]. (3) Multivariate Logistic regression analysis showed that SUP ≥ 3 days group was associated with more GIB than that of non-SUP group [odds ratio (OR) = 1.84, 95% confidence interval (95%CI) was 1.07-3.08, P = 0.030], and the incidence of GIB was less in SUP < 3 days group than that of non-SUP group (OR = 0.57, 95%CI was 0.34-0.94, P = 0.020). When compared with non-SUP group, the risk of secondary pneumonia was increased both in SUP ≥ 3 days group and SUP < 3 days group (OR values were 2.95 and 1.34, 95%CI were 2.10-4.13 and 1.01-1.77, P values were < 0.001 and 0.040, respectively).

CONCLUSIONS: Among critically ill adult patients with sepsis at risk for GIB, SUP showed no effect on reducing in-hospital mortality, the rate of GIB and CDI, but was associated with increased risk of secondary pneumonia and prolonged LOS.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Huang M, Kuang L, Han M, et al. [Efficacy and safety of stress ulcer prophylaxis in septic patients: a retrospective cohort study based on large database]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34296679. doi:10.3760/cma.j.cn121430-20210402-00504

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。